Last reviewed · How we verify
YL201
YL201 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
YL201 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.
At a glance
| Generic name | YL201 |
|---|---|
| Also known as | Serplulimab, Platinum |
| Sponsor | MediLink Therapeutics (Suzhou) Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, YL201 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased blood glucose levels. This mechanism is primarily used to treat type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- A Phase III Study Evaluating YL201 Versus ICC in 2L ESCC (PHASE3)
- A Study YL201 in Patients With Selected Advanced Solid Tumors (PHASE1, PHASE2)
- A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) (PHASE1)
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (PHASE1, PHASE2)
- A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. (PHASE1, PHASE2)
- A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors (PHASE1, PHASE2)
- A Study of YL201 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YL201 CI brief — competitive landscape report
- YL201 updates RSS · CI watch RSS
- MediLink Therapeutics (Suzhou) Co., Ltd. portfolio CI